INTRODUCTION {#s1}
============

Cancer is characterized by genetic and epigenetic aberrations. DNA methylation, an important epigenetic mark that is dysregulated in many cancers, predominantly occurs on the C-5 atom of cytosine in the context of CpG islands in mammals (5-mC) and modulates gene activity by interacting with methyl-binding proteins \[[@R1]\]. TET enzymes, a family of Fe(II)- and α-ketoglutarate (α-KG)-dependent dioxygenases, convert 5-mC to 5-hmC, which can be further converted to 5-fC and 5-caC by the same enzymes \[[@R2]--[@R4]\]. The generation of 5-hmC induces the reversal of the gene silencing effect of 5-mC because 5-hmC is not recognized by transcriptional repressors such as methyl-CpG binding domain proteins (MBD) \[[@R5], [@R6]\].

Penn et al. first discovered 5-hmC in the 1970s, and 5-hmC has since been detected in a variety of tumor tissues \[[@R7]--[@R9]\]. 5-hmC levels are decreased in various malignancies, including glioblastoma, melanoma, breast, prostate, hepatic, gastric and renal cancers \[[@R10]--[@R16]\]. Lian et al. observed that the loss of 5-hmC is an epigenetic hallmark of melanoma and that decreased 5-hmC levels are associated with poorer melanoma outcome \[[@R10]\]. Liu et al. observed that 5-hmC levels are decreased in hepatic cancer and that low 5-hmC is an independent prognostic indicator of both overall survival and time to recurrence \[[@R14]\]. Several recent studies have demonstrated that low 5-hmC expression is associated with poor prognosis in renal cell carcinoma, gastric and ovarian cancers \[[@R13], [@R15], [@R17]\]. However, controversial results have been reported. Strand et al. reported that decreased 5-hmC in prostate cancer was associated with improved biological disease-free survival \[[@R12]\]. Hence, we performed a systematic review of the current evidence using a meta-analysis to analyze the association between 5-hmC levels and the clinicopathological characteristics in several types of cancers and to investigate the value of 5-hmC in the prognosis indication of cancer patients.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

We initially identified four hundred thirty-three potentially relevant studies, and after reviewing the titles and abstracts, fifty-eight articles consistent with our search criteria were chosen for further screening. After careful evaluation, forty-eight studies with insufficient data were excluded. Ultimately, ten studies were chosen for the final analysis (Figure [1](#F1){ref-type="fig"}). The articles included one hepatocellular carcinoma study, one glioblastoma study, one gastric cancer study, one esophageal squamous cell carcinoma study, one prostate cancer study, one ovarian cancer study, one intrahepatic cholangiocarcinoma study, one kidney cancer study, one breast cancer study and one cervical cancer study \[[@R11], [@R12], [@R14]--[@R21]\]. The characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}.

![Flow diagram of the selection process](oncotarget-08-1944-g001){#F1}

###### The characteristics of the included studies

  Author   Year   Country   Cancer type     Patients\' number   Detection methods   Cut-off for 5-hmC low expression
  -------- ------ --------- --------------- ------------------- ------------------- ----------------------------------------------------------
  Orr      2012   America   Glioblastoma    69                  IHC                 H-score in the first quartile
  Yang     2013   China     GC              108                 DNA dot blot        \< median value
  Liu      2014   China     HCC             318                 IHC                 \< median value
  Murata   2015   Japan     ESCC            95                  ELISA               \< median value
  Strand   2015   Denmark   PC              311                 IHC                 Scores 0 and 1 were considered as low expression
  Zhang    2015   China     EOC             130                 IHC                 − and + were considered as low expression
  Dong     2015   China     ICC             123                 IHC                 NR
  Chen     2015   China     Kidney cancer   185                 IHC                 ≤10% cells are positive for IHC staining
  Tsai     2015   China     Breast cancer   257                 IHC                 The score range from 0-7, the cutoff set at a value of 3
  Zhang    2016   China     CSCC            140                 IHC                 − and + were considered as low expression

Abbreviations: HCC, hepatocellular carcinoma; GC, gastric cancer; ESCC, esophageal squamous cell carcinoma; PC, prostate cancer; EOC, epithelial ovarian cancer; ICC, intrahepatic cholangiocarcinoma; CSCC, cervical squamous cell carcinoma; NR, not reported; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay

Meta-analysis results {#s2_2}
---------------------

Data relating to lymph node metastasis, TNM stage, histology grade and survival were extracted and are presented in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### The clinicopathological characteristics of the cases with positive/high 5-hmC and cases with the negative/low 5-hmC in tumor tissues

  Study    Year   Cases (positive/high 5-hmC)   Cases (negative/low 5-hmC)                                                               
  -------- ------ ----------------------------- ---------------------------- ---- ---- ---- ----- ---- ------- ---- ---- ---- ---- ----- ----
  Yang     2013   50                            27                           23   30   20   25    25   58      15   43   13   45   27    31
  Liu      2014   159                           NR                           NR   NR   NR   115   44   159     NR   NR   NR   NR   129   30
  Murata   2015   48/46                         14                           34   19   27   43    5    47/46   16   31   20   26   32    15
  Zhang    2015   34                            18                           16   23   11   30    4    96      29   67   34   62   67    29
  Dong     2015   20                            19                           1    18   2    9     11   103     74   29   68   35   52    51
  Zhang    2016   43                            32                           11   NR   NR   35    8    97      55   42   NR   NR   56    41

###### The HR value and 95%CI of OS and DFS in each study

  Study    Year   OS     DFS         Survival results               
  -------- ------ ------ ----------- ------------------ ----------- ------
  Orr      2012   2.28   1.16-4.49   NA                 NA          poor
  Yang     2013   2.55   1.30-4.98   NA                 NA          poor
  Liu      2014   3.16   2.12-4.74   NA                 NA          poor
  Chen     2015   2.22   1.19-4.17   NA                 NA          poor
  Dong     2015   1.45   1.08-1.93   1.36               1.02-1.81   poor
  Strand   2015   NA     NA          0.62               0.44-0.87   well
  Tsai     2015   NA     NA          1.90               1.20-3.02   poor
  Zhang    2015   2.03   1.22-3.46   NA                 NA          poor
  Zhang    2016   2.02   0.93-7.16   2.56               1.06-6.24   poor

Five studies that collectively including 596 cases were used to evaluate the relationship between 5-hmC levels and lymph node metastasis. Meta-analysis using the random-effect model revealed that the negative/low expression rate of 5-hmC was higher in cancer patients with positive LN metastasis than in those with negative LN metastasis. The association of negative/low 5-hmC level and positive lymph node metastasis was statistically significant in different cancers \[OR = 2.20, 95% CI = 1.23-3.96, *P* = 0.008\] (Figure [2A](#F2){ref-type="fig"}).

![Correlation of 5-hmC levels and cancer stages\
**A.** Forest plots of the association between negative/low 5-hmC levels and lymph node metastasis (positive vs negative). **B.** Forest plots of the association between negative/low 5-hmC levels and TNM stage (III/IV stage vs I/II stage). **C.** Forest plots of the association between negative/low 5-hmC levels and histological differentiation grade (poor vs well/moderate). The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-1944-g002){#F2}

Four studies collectively including 453 cases were used to evaluate the relationship between the 5-hmC level and TNM stage of cancer. Meta-analysis using the random-effect model demonstrated that the negative/low expression rate of 5-hmC was higher in cancer patients with TNM III/IV stage than in those with I/II stage. The association of negative/low 5-hmC levels and advanced TNM stage was statistically significant in different cancers \[OR = 2.89, 95% CI = 1.21-6.92, *P* = 0.017\] (Figure [2B](#F2){ref-type="fig"}).

Six studies collectively including 914 cases were used to evaluate the relationship between the 5-hmC level and histology grade of cancer. These six studies reported decreased 5-hmC in the poor differentiation group compared to the well-moderate differentiation group; however, meta-analysis using the random-effect model revealed no significant main effect \[OR = 1.57, 95% CI = 0.79-3.13, *P* = 0.195\] (Figure [2C](#F2){ref-type="fig"}).

Seven studies reported overall survival (OS) of 1073 cancer patients, and four studies reported the disease-free survival (DFS) of 831 cancer patients according to 5-hmC level in tumor tissues. The fixed-effect model and random-effect model were used to calculate the pooled HR with corresponding 95% CI for OS and DFS, respectively. The meta-analysis results showed that negative/low 5-hmC levels were significantly associated with poor survival of patients with various cancers \[OS: HR = 1.76, 95% CI = 1.41-2.11, *P* \< 0.001; DFS: HR = 1.28, 95% CI = 0.60-1.96, *P* \< 0.001\] (Figure [3](#F3){ref-type="fig"}). These results suggest that negative/low 5-hmC levels might be an indicator of poor prognosis for cancer patients.

![Prognostic value of negative/low 5-hmC levels in patients with cancer\
**A.** Meta-analysis of the association between negative/low 5-hmC levels and overall survival in various cancers. **B.** Meta-analysis of the association between negative/low 5-hmC levels and disease-free survival in various cancers.](oncotarget-08-1944-g003){#F3}

Tests of heterogeneity {#s2_3}
----------------------

The inter-study heterogeneity among the included studies were assessed using the *Q* test. Moderate to high heterogeneity was detected in the data on the association of negative/low 5-hmC with positive lymph node metastasis (*P* = 0.097, *I^2^* = 49.0%), advanced TNM stage (*P* = 0.018, *I^2^* = 70.2%), poor pathological differentiation (*P* = 0.001, *I^2^* = 74.5%), and poor DFS (*P* \< 0.001, *I^2^* = 83.1%); thus, the random-effects models were used for these analyses. There was no obvious heterogeneity in the data on the association of 5-hmC with OS (*P* = 0.229, *I^2^* = 26.2%); thus, the analysis was performed using a fixed-effects model. To explore the source of heterogeneity, stratified analyses by detection method were performed (Figure [4](#F4){ref-type="fig"}), which revealed that heterogeneity could be reduced in all analyses except histology grade.

![Stratified analyses of the association between 5-hmC levels and lymph node metastasis A., TNM stage B., and histological differentiation grade C. were performed by detection methods](oncotarget-08-1944-g004){#F4}

Publication bias {#s2_4}
----------------

We assessed potential publication bias statistically using Begg\'s and Egger\'s tests (Figure [5](#F5){ref-type="fig"}). The funnel plots were symmetrical, and the results of the Begg\'s and Egger\'s tests revealed no publication bias (Begg\'s test, *P* \> 0.05; Egger\'s test, *P* \> 0.05).

![The Begg\'s funnel plots and Egger\'s publication bias plots assessing the publication bias in analyses of the association of 5-hmC levels with lymph node metastasis A., TNM stage B., overall survival C., and disease-free survival D](oncotarget-08-1944-g005){#F5}

DISCUSSION {#s3}
==========

DNA methylation is one of the most-studied epigenetic modifications and plays an important role in carcinogenesis \[[@R22]\]. DNA methylation occurs predominately on the C-5 atom of cytosine in the context of CpG islands in mammals (5-mC) and is associated with the alteration of chromatin organization and modulation of gene activity \[[@R23]\]. 5-mC can be converted to 5-hmC by TET family enzymes \[[@R3]\], and the generation of 5-hmC modulates 5-mC-dependent gene regulation. Thus, 5-hmC might be a potential diagnostic, prognostic and predictive marker for cancers \[[@R24]--[@R26]\]. Ha et al. observed that immuno-assessment of 5-hmC could diagnostically differentiate benign and malignant melanocytic neoplasms; 88% of nevi were positive for 5-hmC, whereas only 31% of melanomas were 5-hmC positive. Moreover, nodular, lentigo maligna and desmoplastic melanoma did not exhibit positive 5-hmC, whereas 47% of the remaining melanoma subtypes and metastases melanoma were 5-hmC positive \[[@R27]\]. Liu et al. reported that 5-hmC correlated with less aggressive tumor behavior in hepatic cancer, and low 5-hmC levels were associated with poor survival and could serve as a prognostic marker for HCC \[[@R14]\]. However, the relationship between 5-hmC levels and survival in other cancers is still not completely understood. Moreover, the clinical significance of 5-hmC in various cancers remains controversial. To our knowledge, the present study is the first to evaluate the correlation between 5-hmC levels and the prognosis of various cancers. Our meta-analysis provides evidence of a significant association between negative/low 5-hmC levels and lymph node metastasis and advanced TNM stage in different cancers. More importantly, negative/low 5-hmC levels were significantly associated with poorer OS and DFS of cancer patients, suggesting that 5-hmC might be a prognostic marker for cancers.

Decreased 5-hmC levels in malignant tumors could be due to the mutation of TET genes or the mutations of isocitrate dehydrogenase 1 or 2 (IDH1/2), as mutation of IDH1/2 produces 2-hydroxyglutarate (2-HG) to inhibit the activity of TET proteins \[[@R28], [@R29]\]. Moreover, other studies have suggested that decreased 5-hmC levels might be caused by decreased TET1/2/3 expression \[[@R30], [@R31]\]. Decreased 5-hmC levels can be detected by various methods, including IHC, DNA dot blot, ELISA, and mass spectrometry. In our study, two papers included data from non-IHC detection that revealed high heterogeneity in the comparison of negative/low 5-hmC and lymph node metastasis and TNM stage. However, the high heterogeneity in the comparison of the association of negative/low 5-hmC levels with pathological differentiation grade was not significantly decreased by stratified analyses, suggesting that other factors, such as cancer type and varying cutoff values may be involved in the heterogeneity, which need to be further confirmed in future studies.

Although this systematic review aimed to provide a comprehensive estimate of the clinical significance of altered 5-hmC levels in various types of cancer, several limitations remain. First, the numbers of studies and patients included in this analysis were relatively small. Second, most of the studies were based on Asian populations, and only two studies analyzed the data in Caucasian populations. Third, low levels and loss of 5-hmC expression were reported together, preventing the evaluation of the difference between the associations of low and loss of 5-hmC expression with clinical parameters of cancer. Additional studies are needed to confirm these results.

In conclusion, our results indicate that advanced TNM stage and positive lymph node metastasis are more frequent in patients with negative/low levels of 5-hmC. Furthermore, we provide evidence for an association of negative/low 5-hmC with poor OS and DFS in various cancers. Therefore, decreased 5-hmC appears to be a valuable prognostic factor for cancers.

MATERIALS AND METHODS {#s4}
=====================

Publication search strategy {#s4_1}
---------------------------

A comprehensive literature search of PubMed, EMBASE, Web of Science and the Cochrane Library was performed up to March 2016. Search terms included "5-hydroxymethylcytosine OR 5-hmC OR 5hmC OR 5 hmC" combined with "neoplasm OR neoplasia OR tumor OR cancer." Additional relevant references cited in the retrieved articles were also evaluated.

Selection criteria {#s4_2}
------------------

To be eligible for inclusion in the systematic review, a study was required to meet the following criteria: (1) detected 5-hmC levels in tumor tissues from any type of solid tumor, rather than in serum, cell lines or any other type of specimen; (2) published in English with full text available; (3) compared the difference between at least two groups (for example, positive/high 5-hmC compared to negative/low 5-hmC); (4) hazard ratios for OS or DFS with 95% CIs were available. Based on these criteria, ten eligible studies were included in this meta-analysis.

Data collection {#s4_3}
---------------

Publication characteristic details, such as the first author\'s name, publication year, patients\' country, the number of patients, cancer type, detection methods, clinicopathological features, the cut-off definition of low 5-hmC and the HR for OS and/or DFS with corresponding 95% CIs were collected. When both univariate analysis and multivariate analysis were reported, the results of the multivariate analysis were used for analysis.

Statistical analysis {#s4_4}
--------------------

All statistical analyses were performed using the STATA 12.0 software package (Stata Corporation, College Station, TX, USA). The associations between 5-hmC levels and lymph node metastasis, TNM stage and histology grade were evaluated by calculating the ORs and corresponding 95% CIs. For survival data, the HRs with 95% CIs were extracted, and pooled HRs and corresponding 95% CIs were calculated. The Cochrane *Q* test *(P* \< 0.10 indicated a high level of statistical heterogeneity) and *I*^2^ (values of 25%, 50% and 75% corresponding to low, moderate and high degrees of heterogeneity, respectively) were used to assess the heterogeneity among eligible studies \[[@R32]\]. When no statistically significant heterogeneity was observed, a pooled effect was calculated using a fixed-effects model; otherwise, a random-effects model was used. Publication bias was evaluated using Begg\'s and Egger\'s tests. All *P* values in the meta-analysis were two-sided, and a *P* value of less than 0.05 was considered significant.

This work was supported by the National Natural Science Foundation of China (81301851) and The National Key Basic Research Development Plan (973 Plan 2014CB542006).

**CONFLICTS OF INTEREST**

No potential conflicts of interest are disclosed.
